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Aims To determine the association between obesity and outcomes in post-acute myocardial infarction (AMI) patients with
systolic heart failure (HF).
Methods
and results
Of the 6632 Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) par-
ticipants, 6611 had data on baseline body mass index (BMI) and 6561 had BMI ≥ 18.5 kg/m2. Of these, 1573 were
obese (BMI ≥ 30 kg/m2) and 4988 were non-obese (BMI 18.5–29.9 kg/m2). Propensity scores for obesity, estimated
for each patient, were used to assemble a cohort of 1519 pairs of obese and non-obese patients who were balanced
on 65 baseline characteristics. All-cause mortality occurred in 13.7 and 13.8% of matched obese and non-obese
patients, respectively, during 16 months of median follow-up [matched hazard ratio (HR) for obesity 0.98; 95%
confidence interval (CI) 0.79–1.21; P ¼ 0.831]. Before matching, the obese group was younger (mean age, 62 vs.
64 years; P , 0.0001) and had more women (37 vs. 26%; P , 0.0001). The paradoxical pre-match association
between obesity and reduced mortality (unadjusted HR 0.82; 95% CI 0.70–0.95; P ¼ 0.008) disappeared when
adjusted for age alone (age-adjusted HR 0.91; 95% CI 0.78–1.06; P ¼ 0.206) but not for gender alone (gender-
adjusted HR 0.79; 95% CI 0.68–0.92; P ¼ 0.003). Obesity had no association with mortality in 1573 pairs of age-
matched obese and non-obese patients (age-adjusted HR 0.94; 95% CI 0.77–1.13; P ¼ 0.484).
Conclusion In post-AMI patients with systolic HF, obesity provides no independent intrinsic survival benefit. The paradoxical
unadjusted survival associated with obesity is largely explained by the younger age of obese patients.
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Introduction
Obesity is a risk factor for cardiovascular disorders such as acute
myocardial infarction (AMI) and heart failure (HF).1,2 However,
the impact of obesity on outcomes in patients with cardiovascular
disease is often complex.3 –13 Although obesity is associated with
reduced mortality in HF,3 –5 in patients with AMI, obesity has
been variably described to have a positive, neutral, or negative
association with mortality.6– 13 These variations have been attribu-
ted to methodological differences of these studies and residual
bias. Residual bias is a source of concern in studies using traditional
regression-based multivariable risk adjustments as baseline distri-
bution of covariate may not be balanced in these studies.14
Further, studies using traditional regression-based risk adjustment
models suffer from lack of blinding as these adjustments require
access to study outcomes.15 Studies based on propensity score
matching, on the other hand, allow assembly of study populations
in which exposed and unexposed groups are balanced on all
measured baseline covariates.14– 16 Additionally, propensity-
matched studies can mimic a key feature of randomized clinical
trials, that is, investigators are blinded to study outcomes during
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the assembly of the balanced study cohorts.15 Therefore, the
objective of this study was to determine causal associations
between obesity and outcomes in a propensity-matched popu-
lation of post-AMI HF patients.
Methods
Source of data
The Eplerenone Post-Acute Myocardial Infarction Heart Failure Effi-
cacy and Survival Study (EPHESUS) was a multicenter, randomized,
clinical trial of eplerenone in post-AMI patients with left ventricular
systolic dysfunction (LVSD) and transient clinical HF.17 AMI was docu-
mented by standard criteria.17 Patients were randomized 3–14 days
after their AMI to receive eplerenone (n ¼ 3319) or placebo (n ¼
3313). Patients were receiving standard medical and reperfusion thera-
pies including angiotensin-converting enzyme (ACE) inhibitors or
angiotensin receptor blockers and beta-blockers. LVSD was documen-
ted by left ventricular ejection fraction ,40% and HF was documented
by presence of pulmonary râles, a third heart sound, or chest X-ray
evidence of pulmonary venous congestion. Left ventricular systolic dys-
function and HF were required to occur after the index AMI and
before randomization. Post-AMI patients with diabetes mellitus and
LVSD could be enrolled even if they did not have clinical HF as they
were considered to have similar cardiovascular risk as non-diabetic
patients with LVSD and HF symptoms.17,18 However, 69% (1483/
2142) of patients with diabetes had clinical HF.
Baseline body mass index
Baseline body mass index (BMI) was systematically measured during
standard physical exams performed during the study screening
visit.19 Of the 6632 EPHESUS participants, baseline BMI data were
available for 6611 patients. For the purposes of this analysis, we
excluded 50 patients who were underweight (BMI , 18.5 kg/m2)
because of the established poor prognosis associated with cachexia
in HF.20 Of the remaining 6561 patients with BMI ≥ 18.5 kg/m2, 1573
were obese (BMI ≥ 30 kg/m2) and 4988 were non-obese (BMI 18.5–
29.9 kg/m2). Of the 4988 non-obese patients, 2967 were overweight
(BMI 25–29.9 kg/m2) and 2021 were normal-weight (BMI 18.5–
24.9 kg/m2).
Study outcomes
The primary and co-primary end points of the EPHESUS trial, all-cause
mortality and the combined end point of cardiovascular hospitalization
or cardiovascular mortality, were also the primary end points for the
current analysis. Secondary outcomes included other major secondary
end points from EPHESUS such as cardiovascular mortality and all-
cause and cardiovascular hospitalization.17 The cause of death or the
primary diagnosis leading to hospitalization was adjudicated by a
blinded independent EPHESUS critical events committee.17,19
Assembly of a balanced study cohort
Because of the imbalances in baseline characteristics between obese
and non-obese patients, we used propensity score matching to assem-
ble a cohort in which all measured baseline characteristics between
obese and non-obese patients would be balanced.15,16 The propensity
score for obesity for a patient would be that patient’s probability of
being obese given his or her measured baseline characteristics. We
estimated propensity scores for obesity for all 6561 patients using a
non-parsimonious multivariable logistic regression model based on
65 baseline characteristics displayed in Figure 1.21 –25 Using a greedy
matching protocol, we were able to match 1519 of the 1573 obese
(BMI ≥ 30 kg/m2) patients with 1519 non-obese (BMI 18.5–29.9 kg/
m2) patients who had similar propensity scores.21– 25
The efficacy of the regression model used to estimate propensity
score is best assessed by its ability to reduce bias and achieve balance
in the distribution of baseline characteristics between two groups
after matching.26,27 Because propensity score models are sample-
specific adjusters and are not intended to be used for out-of-sample
prediction or estimation of coefficients, measures of fitness, and
discrimination are not important for the assessment of the model’s
effectiveness.26,27 Therefore, we assessed pre-match imbalance and
post-match balance by estimating absolute standardized differences
for baseline characteristics between obese and non-obese patients
and presented them as Love plots.26,28,29 Absolute standardized differ-
ences directly quantify the bias in the means (or proportions) of covari-
ates across the groups. These differences are expressed as a percentage
of the pooled standard deviations.28,29 Absolute standardized differ-
ences are not confounded by sample size and thus can compare
balance in the initial sample with that in the matched sample.26 An absol-
ute standardized difference of 0% indicates no residual bias and values
,10% are considered of inconsequential bias. As illustrated in
Figure 1, the absolute standardized differences of all the baseline charac-
teristics were ,10% after matching suggesting substantial bias reduction
and the efficacy of our propensity score model.
Statistical analysis
For descriptive analyses, we used Pearson x2 and Wilcoxon rank-sum
tests for the pre-match, and McNemar’s test and paired sample t-test
for the post-match comparisons of baseline characteristics of obese
and non-obese patients, as appropriate. We used Kaplan–Meier
plots and matched Cox regression analyses to estimate association
between obesity and outcomes during 16 months of median
(maximum 30 months) follow-up. All statistical tests were evaluated
using two-tailed 95% confidence levels, and data analyses were per-
formed using SPSS 15 for Windows.30 The authors had full access to
the data and take responsibility for its integrity.
Before matching, obese patients were younger with fewer women,
and had a higher prevalence of hypertension and diabetes. Therefore,
we examined the effect of these covariates on the unadjusted associ-
ation between obesity and mortality by separately adjusting for each of
these covariates. Because of the substantial effect of age on the unad-
justed association between obesity and mortality observed during
preliminary analyses, we examined the association between obesity
and mortality in an age-matched cohort of 1573 pairs of patients in
which both groups had the same mean (+SD) age of 62.03
(+10.90) years but had imbalances in the distribution of other base-
line characteristics.
Sensitivity analysis
To determine if the association between BMI and mortality could be
reproduced using a different cut-off of BMI, we categorized patients
into overweight/obese (BMI ≥ 25 kg/m2) and normal-weight (BMI
18.5–24.9 kg/m2). We chose BMI 25 kg/m2 as the cut-off as prelimi-
nary data from our pre-match patients suggest that unadjusted mor-
tality for patients with BMI 25–29.9 and .30 kg/m2 were similar
(about 14% each) and that for those with BMI 18.5–22.5 and 22.5–
24.9 kg/m2 were also similar (about 18% each). As described above,
we estimated propensity scores for being overweight/obese for each
patient and then assembled a matched cohort of 1890 pairs of normal-
weight and overweight/obese patients who were balanced on 65 base-
line characteristics. We then used matched Cox regression analyses to
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estimate association between being overweight/obese and outcomes
during 16 months of median (maximum 32 months) follow-up.
Results
Baseline characteristics
Matched patients had a mean (+SD) age of 62 (+11) years, 1080
(36%) were women and 249 (8%) were non-whites. Before match-
ing, obese patients were younger (62 vs. 64 years; P , 0.0001)
and had higher prevalence of women (37 vs. 26%; P , 0.0001),
hypertension (72 vs. 57%; P , 0.0001), and diabetes mellitus
(43 vs. 29%; P , 0.0001; Table 1). These and other pre-match
imbalances between non-obese (BMI 18.5–29.9 kg/m2) and
obese (BMI ≥30 kg/m2) patients were balanced after matching
(Tables 1 and 2). The mean (+SD) BMI’s for non-obese and
obese patients before matching were 26 (+2.6) and 36 (+3.5)
kg/m2, respectively, and the respective mean BMI after matching
were 26 (+2.6) vs. 33 (+3.5) kg/m2, respectively.
Association between body mass index
≥30 kg/m2 and outcomes
Overall, 418 (13.8%) matched patients died from all causes during
16 months of median follow-up. All cause mortality occurred in
13.7% (rate, 1012/10 000 person-years) and 13.8% (rate, 1053/
10 000 person-years) of obese and non-obese patients, respect-
ively (hazard ratio (HR) when obese patients were compared
with non-obese patients 0.98; 95% confidence interval (CI)
0.79–1.21; P ¼ 0.831; Figure 2A and Table 3). The relationship
between obesity and mortality was not modified by therapy with
eplerenone (data not shown).
Among 6561 pre-match patients, all-cause mortality occurred in
13.5 and 16.0% of obese and non-obese patients respectively (HR
0.82, 95% CI 0.70–0.95; P ¼ 0.008; Table 3). However, this associ-
ation lost significance when adjusted for all covariates displayed in
Figure 1 (HR 0.92; 95% CI 0.79–1.08; P ¼ 0.329) and propensity
scores based on all covariates displayed in Figure 1 (HR 0.96;
95% CI 0.82–1.12; P ¼ 0.601; data not shown). When we used
BMI as a continuous variable, each unit increase in BMI was associ-
ated with a significant 3% decrease in mortality before matching
(unadjusted HR 0.97; 95% CI 0.96–0.99; P , 0.0001) but had no
significant association with mortality after matching (HR 0.99;
95% CI 0.97–1.01; P ¼ 0.372; data not shown). Obesity had no
association with the EPHESUS co-primary combined end points
of cardiovascular hospitalization or cardiovascular mortality
among matched patients (HR 1.02; 95% CI 0.87–1.18; P ¼ 0.848;
Table 3). Associations of BMI ≥ 30 kg/m2 and the other secondary
end points are displayed in Table 3.
Figure 1 Love plot for absolute standardized differences before and after propensity score matching comparing covariate values between
participants with body mass index 18.5–30 and ≥30 kg/m2 (ACE, angiotensin-converting enzyme; MI, myocardial infarction).
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Table 1 Baseline patient characterics by body mass index (BMI)
n (%) or mean (+SD) Before propensity matching After propensity matching
BMI 18.5–29.9 kg/m2 (n 5 4988) BMI ≥ 30 kg/m2 (n 5 1573) P-value BMI 18.5–29.9 kg/m2 (n 5 1519) BMI ≥ 30 kg/m2 (n 5 1519) P-value
Age, years 64 (+12) 62 (+11) ,0.0001 62 (+12) 62 (+11) 0.220
Women 1303 (26) 582 (37) ,0.0001 531 (35) 549 (36) 0.502
Non-white race 508 (10) 129 (8) 0.021 121 (8) 128 (8) 0.692
Smoking status
Current smokers 1599 (32) 423 (27) ,0.0001 430 (28) 417 (28) 0.926
Never smokers 1888 (38) 674 (43) 631 (42) 648 (43)
Former smokers 1501 (30) 476 (30) 458 (30) 454 (30)
Days of hospital stay during index AMI 15 (+10) 15 (+9) 0.103 15 (+9) 15 (+9) 0.798
ST elevation during index AMI 3542 (71) 1110 (71) 0.735 1077 (71) 1071 (71) 0.842
Past medical history
Acute myocardial infarction 1373 (28) 415 (26) 0.375 413 (27) 399 (26) 0.594
Angina pectoris 2051 (41) 661 (42) 0.526 614 (40) 636 (42) 0.427
Hypertension 2850 (57) 1129 (72) ,0.0001 1070 (70) 1077 (71) 0.799
Diabetes mellitus 1453 (29) 671 (43) ,0.0001 635 (42) 625 (41) 0.718
Chronic kidney disease 3304 (66) 1009 (64) 0.127 995 (66) 974 (64) 0.456
Heart failure 713 (14) 250 (16) 0.118 228 (15) 243 (16) 0.478
Killip status
I 733 (15) 314 (20) ,0.0001 261 (17) 298 (20) 0.347
II 3277 (66) 953 (61) 974 (64) 923 (61)
III 814 (16) 266 (17) 238 (16) 260 (17)
IV 164 (3) 40 (3) 46 (3) 38 (3)
Blood pressure, mm Hg
Systolic 118 (+16) 122 (+17) ,0.0001 122 (+17) 122 (+17) 0.542
Diastolic 72 (+10) 74 (+11) ,0.0001 74 (+11) 74 (+11) 0.488
Pulse, beats per minute 74 (+12) 75 (+12) 0.001 75 (+12) 75 (+12) 0.884
Creatinine, mg/dL 1.13 (+0.33) 1.12 (+0.33) 0.363 1.12 (+0.32) 1.12 (+0.33) 0.622
Glucose, mg/dL 131 (+68) 142 (+64) ,0.0001 140 (+70) 141 (+64) 0.710
Uric acid, mg/dL 6.3 (+3.2) 7.1 (+15.6) ,0.0001 6.6 (+5.0) 7.1 (+15.9) 0.151
Albumin, g/dL 3.70 (+0.60) 3.76 (+0.58) 0.001 3.78 (+0.64) 3.76 (+0.58) 0.279
Total protein, g/dL 6.87 (+1.83) 7.01 (+2.32) 0.013 7.03 (+2.45) 7.01 (+2.34) 0.779
Total cholesterol, mg/dL 192 (+48) 199 (+50) ,0.0001 200 (+50) 199 (+50) 0.302
Triglyceride, mg/dL 164 (+109) 189 (+101) ,0.0001 192 (+160) 186 (+98) 0.258















Association between body mass index
≥25 kg/m2 and outcomes
Among 1890 pairs of propensity-matched normal-weight (BMI
18.5–24.9) and overweight/obese patients (BMI ≥ 25), all-cause
mortality occurred in 18.2 and 16.4% of matched normal-weight
and overweight/obese patients (matched HR when overweight/
obese patients were compared with normal-weight patients 0.87;
95% CI 0.74–1.03; P ¼ 0.104; data not shown). Among all 6561
pre-match patients, unadjusted and propensity-adjusted HR for all-
cause mortality associated with overweight/obesity were 0.74; 95%
CI 0.65–0.84; P , 0.0001 and 0.87;95% CI 0.76–0.997; P ¼ 0.046;
data not shown.
Impact of age on the association between
body mass index ≥30 kg/m2 and
outcomes
The significant paradoxical pre-match association between obesity
and reduced mortality (unadjusted HR 0.82; 95% CI 0.70–0.95;
P ¼ 0.008; Table 3) was eliminated after adjustment for age alone
(age-adjusted HR 0.91; 95% CI 0.78–1.06; P ¼ 0.206; Table 4) but
not after adjustment for gender (gender-adjusted HR 0.79; 95% CI
0.68–0.92; P ¼ 0.003), hypertension (hypertension-adjusted HR
0.80; 95% CI 0.68–0.93; P ¼ 0.003) or diabetes (diabetes-adjusted
HR 0.77; 95% CI 0.66–0.89; P ¼ 0.001; data not shown). Among
the 1573 pairs of age-matched patients, obesity (BMI ≥ 30 kg/m2)
had no association with mortality (age-adjusted HR when obese
patients were compared with non-obese patients 0.94; 95% CI
0.77–1.13; P ¼ 0.484; Figure 2B). Among these patients, when BMI
was used as a continuous variable, it had no significant association
with all-cause mortality (unadjusted HR 0.99; 95% CI 0.97–1.01;
P ¼ 0.165; data not shown).
Discussion
The results of the current analysis demonstrate that obesity was
associated with reduced all-cause mortality among post-AMI
patients with LVSD and HF but this association was not intrinsic
in nature. The unadjusted mortality reduction associated with
obesity may in part be explained by imbalances in baseline
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Table 2 Baseline therapy by body mass index (BMI)
n (%) or mean (+SD) Before propensity matching After propensity matching
BMI 18.5–29.9
kg/m2 (n 5 4988)
BMI ≥ 30 kg/m2
(n 5 1573)
P-value BMI 18.5–29.9
kg/m2 (n 5 1519)




revascularization within 14 daysa
2226 (45) 752 (48) 0.027 705 (46) 723 (48) 0.528
Coronary artery bypass graft 43 (1) 27 (2) 0.004 18 (1) 23 (2) 0.522
Percutaneous coronary
intervention
1170 (24) 404 (26) 0.071 386 (25) 386 (25) 1.000
Thrombolysis 1322 (27) 431 (27) 0.484 409 (27) 414 (27) 0.870
Medications
Eplerenone 2481 (50) 804 (51) 0.342 760 (50) 770 (51) 0.745
Angiotensin-converting enzyme
inhibitors
4179 (84) 1380 (88) ,0.0001 1316 (87) 1331 (88) 0.448
Angiotensin-receptor blocker 161 (3) 54 (3) 0.690 55 (4) 53 (4) 0.923
Beta-blockers 3711 (74) 1214 (77) 0.026 1168 (77) 1167 (77) 1.000
Nitrates 3051 (61) 1026 (65) 0.004 1001 (66) 987 (65) 0.617
Aspirin 4381 (88) 1431 (91) 0.001 1393 (92) 1378 (91) 0.365
Anti-platelet drugs 1423 (29) 475 (30) 0.203 463 (31) 454 (30) 0.187
Anticoagulants 852 (17) 246 (16) 0.182 258 (17) 239 (16) 0.757
Statins 2262 (45) 805 (51) ,0.0001 793 (52) 775 (51) 0.531
Other lipid lowering agents 68 (1) 37 (2) 0.006 35 (2) 33 (2) 0.901
Digoxin 758 (15) 230 (15) 0.578 227 (15) 224 (15) 0.918
Loop diuretics 2716 (55) 902 (57) 0.044 841 (55) 860 (57) 0.504
Other diuretics 387 (8) 151 (10) 0.020 139 (9) 144 (10) 0.803
Potassium supplements 812 (16) 261 (17) 0.769 237 (16) 249 (16) 0.581
Magnesium supplements 188 (4) 70 (5) 0.226 58 (4) 69 (5) 0.371
Alpha-blockers 81 (2) 42 (3) 0.008 39 (3) 37 (2) 0.909
Calcium channel blockers 778 (16) 279 (18) 0.044 251 (17) 263 (17) 0.593
Anti-arrhythmic drugs 609 (12) 161 (10) 0.034 148 (10) 159 (11) 0.544
Glycoprotein IIb/IIIa blockers 36 (1) 25 (2) 0.002 18 (1) 20 (1) 0.871
aThese numbers may not be the exact sum of the three reperfusion or revascularization procedures as some patients received more than one procedures.
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characteristics between obese and non-obese patients, in particu-
lar by the younger age of obese patients. However, when these
imbalances were eliminated after matching or using other meth-
odological approaches, obesity had no association with all-cause
mortality, suggesting lack of a true intrinsic association. To the
best of our knowledge, this is the first report of an association
between obesity and outcomes in a propensity-matched cohort
of post-AMI patients with LVSD and HF.
Previous findings of a paradoxical association between obesity
and reduced mortality have been explained by confounding associ-
ated with higher BMI that are also obvious from pre-match baseline
characteristics in our study. For example, obese patients in our
study were younger and were more likely to be women, both of
which may have given them a survival advantage. However,
obesity was also associated with higher prevalence of hypertension
and diabetes mellitus, which may have increased their mortality
risk. Therefore, the unadjusted mortality reduction associated
with obesity indicates that the confounding by age, gender, and
other favourable baseline characteristics may have been more
powerful than that by hypertension, diabetes, and other unfavour-
able baseline characteristics. However, in models adjusted specifi-
cally for age, either by assembling an age-matched cohort or
adjusting for age alone in a regression model, BMI was no longer
associated with mortality. These findings suggest that the unad-
justed mortality reduction associated with obesity may in large
part be explained by younger age of obese patients and that
there may be no intrinsic association between obesity and
mortality.
Findings from our study are consistent with a recent report that
also demonstrated an unadjusted paradoxical association between
obesity and mortality after AMI which was also eliminated after
multivariable risk adjustment.13 In that study, each unit increase
in BMI was associated with an unadjusted but significant 5%
reduction in 1-year mortality. Similar to our study, when adjusted
for age alone, the association between BMI and mortality became
insignificant. However, unlike the post-AMI patients with LVSD and
HF in our study, patients in that study were older, had higher left
ventricular ejection fraction and the vast majority had Killip class I
symptoms. Further, our propensity score matching allowed us to
assemble a balanced cohort and examine intrinsic associations
between obesity and other outcomes.
Taken together, the findings of these studies may help dispel the
notion of a true obesity paradox in patients with AMI. Adjustment
for age and other covariates did attenuate the significant unadjusted
association between obesity and reduced mortality and made it non-
significant. Interestingly, even adjustment for all these confounder did
not reverse the association to demonstrate an increased risk associ-
ated with obesity. This suggests that the association between obesity
and mortality in post-AMI patients with HF and LVSD is complex and
may not be completely explained by those measured covariates.
However, considering the known association of obesity with tra-
ditional risk factors such as hypertension and diabetes mellitus,
these conditions should be properly managed in post-AMI obese
patients with LVSD and HF. The association between obesity and out-
comes has also been extensively studied in patients with systolic
HF.3,5,31–34 Findings from those studies also suggest that obese
patients were in general younger in age and that the association
between obesity and reduced mortality did not disappear after adjust-
ment for age and other covariates in multivariable regression-based
models.3,5,31–34 However, regression adjustments may not ensure
balance in the distribution of age or other baseline characteristics.14
Further, unlike our study, the association of BMI with mortality was
not examined in a model adjusted for age alone or in an age-matched
cohort. Finally, the differential confounding effect of age may also
be attributed to the differences in study populations. Unlike HF
patients in those studies, patients in our study were post-AMI with
LVSD and HF.
Several limitations of our study must be acknowledged. Patients in
our study were post-AMI with LVSD and HF and were enrolled in a
Figure 2 Kaplan–Meier plots for all-cause mortality for
patients with body mass index (BMI) 18.5–30 and ≥30 kg/m2.
(A) In propensity-matched cohort and (B) In age-matched
cohort (HR, hazard ratio; CI, confidence interval).
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randomized clinical trial which limits generalizability. We used BMI to
define obesity. We had no data on abdominal adiposity, which is con-
sidered a better marker for cardiovascular risk associated with
obesity.35,36 However, abdominal adiposity has not been shown to
have any intrinsic association with mortality.13 We also had no data
on weight changes, a potential marker of cardiac cachexia.31
However, the prevalence of chronic cachexia is probably low as the
prevalence of prior AMI and HF was low and patients with
BMI , 18.5 were excluded. Concern for the loss of patients during
matching is alleviated by our ability to reproduce all key results
among pre-match patients using traditional regression-based analyses.
Confounding by an unmeasured variable is possible. However, that
concern is lessened by the neutral finding from our matched analysis
that did not show any intrinsic association between obesity and
mortality.
In conclusion, despite a higher prevalence of hypertension and
diabetes among obese patients, obesity was associated with an
unadjusted paradoxical reduction in mortality in post-AMI patients
with LVSD and HF. This may be largely explained by the younger
age of the obese patients and suggests the lack of an intrinsic
association with BMI and mortality in these patients. A well-
designed randomized control trial needs to be conducted to pro-
spectively examine whether aggressive management of traditional
cardiovascular risk factors such as hypertension and diabetes can
improve outcomes in obese post-AMI patients with LVSD and HF.
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Table 3 Associations of body mass index (BMI) ≥30 kg/m2 with outcomes in Eplerenone Post-Acute Myocardial
Infarction Heart Failure Efficacy and Survival Study









BMI 18.5–29.9 kg/m2 BMI ≥ 30 kg/m2
Before matching n ¼ 4988 n ¼ 1573




2516 (1409/5600) 2339 (432/1847) 2177 0.95 (0.85–1.06) 0.342
Cardiovascular mortality 1056 (681/6450) 892 (190/2130) 2164 0.86 (0.73–1.01) 0.061
Heart failure mortality 265 (171/6450) 239 (51/2130) 226 0.91 (0.67–1.25) 0.561
All-cause hospitalization 5359 (2238/4176) 5343 (739/1383) 216 1.02 (0.94–1.11) 0.661
Cardiovascular
hospitalization
1652 (925/5600) 1668 (308/1847) +16 1.03 (0.91–1.17) 0.650
Heart failure hospitalization 919 (547/5954) 901 (178/1975) 217 1.00 (0.85–1.19) 0.988
Fatal or non-fatal acute
myocardial infarction
730 (450/6162) 710 (143/2014) 220 0.99 (0.82–1.20) 0.926
After matching n ¼ 1519 n ¼ 1519




2342 (407/1738) 2327 (416/1788) 215 1.02 (0.87–1.18) 0.848
Cardiovascular mortality 903 (180/1994) 910 (187/2056) +7 1.02 (0.82–1.27) 0.865
Heart failure mortality 186 (37/1994) 243 (50/2056) +58 1.09 (0.68–1.77) 0.714
All-cause hospitalization 5496 (698/1270) 5295 (709/1339) 2201 0.99 (0.88–1.13) 0.924
Cardiovascular
hospitalization
1582 (275/1738) 1639 (293/1788) +56 1.06 (0.88–1.27) 0.549
Heart failure hospitalization 837 (155/1851) 890 (170/1910) +53 1.03 (0.81–1.30) 0.810
Fatal or non-fatal acute
xmyocardial infarction
757 (144/1901) 693 (135/1947) 264 0.95 (0.74–1.23) 0.952
aAbsolute differences were calculated by subtracting the percentage of events in the BMI 18.5–29.9 kg/m2 from those in the BMI ≥ 30 kg/m2 group (before values were rounded).
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Table 4 Impact of age on the associations of body mass
index ≥30 kg/m2 with all-cause mortality in Eplerenone
Post-Acute Myocardial Infarction Heart Failure Efficacy
and Survival Study
Outcomes Hazard ratio (95%
confidence interval)
P-value
Adjusted for age 0.91 (0.78–1.06) 0.206
Age-matched 0.94 (0.77–1.13) 0.484
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